A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)

Conclusions The MTD was exceeded at trebananib 10 mg/kg weekly and temsirolimus 20 mg weekly, with frequent overlapping toxicities including fatigue, edema, and anorexia.

http://link.springer.com/10.1007/s10637-015-0313-8

Source: Investigational New Drugs - December 19, 2015 Category: Drugs & Pharmacology Source Type: research